PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Frost & Sullivan
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Frost & Sullivan Award Highlights CIS Pharma's Technology Innovation in Polymer Industry - Award recipient recognised for its innovative and unique Cellophil™
Frost & Sullivan Award Highlights CIS Pharma's Technology Innovation in Polymer Industry


NewswireToday - /newswire/ - London, United Kingdom, 2012/04/11 - Award recipient recognised for its innovative and unique Cellophil™.

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Based on its recent analysis of the responsive polymer for bio-medical application market, Frost & Sullivan recognises CIS Pharma with the 2011 European Frost & Sullivan Technology Innovation Award for its unique Cellophil™ bio-medical polymer technology.

"This novel temperature-responsive polymer, based on bi-functional amino-acids, exhibits superior biocompatibility, while resolving biocompatibility issues such as bio-film and infection-related problems associated with conventional medical-grade polymers for bio-medical use,” remarks Frost & Sullivan Research Analyst Arpita Mukherjee. "The polymer can be loaded with drugs for target-specific release, improving the quality of patient care and addressing unmet medical needs. Drugs can be incorporated into the delivery system, either covalently or based on ionic interactions."

With its intelligent functionally, Cellophil™ is finding strong prospects in various bio-medical applications. It is capable of phase transition and changes from liquid to solid phase when delivered to the human body. The transition temperature is adjustable and is set anywhere in between 30 degrees C to 37 degrees C for medical applications, depending on the desired site of delivery, and the phase transition is reversible.

"The most noticeable factor is that with control over chemical and physical properties such as hydrophilicity, water content, porosity, optical clarity, ultra-violet (UV) absorption, adhesive properties, surface texture, and permeability, drugs delivered site- and target-specific by Cellophil™ drug delivery systems reduce or eliminate the adverse effect of drugs on other body parts," explains Mukherjee. "With such intelligent functionality, Cellophil™ polymer technology opens a wide range of applications for drug delivery, bio-medical implants and replacements."

Based on different Cellophil™ polymers, CIS Pharma is now developing indication-specific bio-medical products that include drug delivery systems for ophthalmology, dermatology and cardiovascular, products for reconstructive indications such as bone-replacement or skin grafting and new materials for intraocular and contact lenses.

"In the field of ophthalmology, Cellophil™ will change the way allergies, dry eye, uveitis and age-related macular degeneration are treated in the near future," says Mukherjee. "Another application in the eye care industry is to hydrophilise the surface of silicon contact lenses for increased contact lens comfort."

In the field of dermatology, Cellophil™ shows improved wound healing properties. It can be washed away and reapplied, another advantage of its thermo-responsiveness. In the cardiovascular arena, dual-drug-eluting stents with improved safety profiles are being developed, with heart valves slated to be the next target.

"Extensive safety studies have confirmed the biocompatibility of Cellophil™ polymers," concludes Mukherjee. "Cellophil™ technology creates new bio-medical applications for polymers; CIS Pharma is set to establish new standards in the field of bio-medical polymers within the next 5 years."

Each year, Frost & Sullivan presents this award to the company that has demonstrated uniqueness in developing a technology, which significantly impacts both the functionality and the customer value of new products and applications. The award lauds the relevance of the innovation to the industry.

Frost & Sullivan Best Practices Awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About CIS Pharma

For over 50 years, CIS Pharma, a drug delivery and pharmaceutical research company headquartered near Basel, Switzerland, has been developing innovative technologies and treatments in the fields of ophthalmology and dermatology. The company discovers, patents, and license-out its novel technologies and products to a wide range of life science companies, that include both start-ups and global market leaders. Applying innovative technology CIS Pharma addresses unmet medical needs and improves patient compliance as well as the safety profile of treatments. With regards to Cellophil™ the company is looking for partners to develop Cellophil™ biomedical polymers with indication-specific properties to address unmet medical needs with drug delivery systems and biomedical implants

About Frost & Sullivan

Frost & Sullivan (, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents.

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Written by / Agency / Source: Frost & Sullivan


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick NewswireToday Visibility Checker


Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

# # #

  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!

Frost & Sullivan Award Highlights CIS Pharma's Technology Innovation in Polymer Industry

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
Publisher Contact: Emily Bailey 
+44(0)20 7915 7869 emily.bailey[.]
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Articles From Frost & Sullivan / Company Profile

Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ipsen Data Presented During ENETS Annual Conference 2020 Capture New Patient and Healthcare Professional Insights in the Treatment of NETs
Global Pharmaceutical Contract Manufacturing Organization Market to Reach 2.14 Billion by 2024 Finds Frost & Sullivan
Ipsen’s Palovarotene Clinical Program in Fibrodysplasia Ossificans Progressiva Reaches Prespecified Interim Analysis Futility Criteria
Global Bio-based Chemicals Market is Expected to Grow At A CAGR of 16.67% by 2027 According to Inkwood Research
Global Diabetes Drugs Market Forecast 2019-2027 Reports Inkwood Research
Dysport® Now Approved in the UK for Symptomatic Treatment of Upper Limb Spasticity in Children with Cerebral Palsy
Human Microbiome Market to Reach .08 Billion by 2023, Powered by the High Growth in Over-the-Counter Probiotics Finds Frost & Sullivan
BASF Launches Hepacor in Switzerland for the Dietary Management of Non-Alcoholic Fatty Liver Disease
FDA Grants Priority Review to Genentech’s Risdiplam for Spinal Muscular Atrophy
Ipsen Presents New Analyses Utilizing Modern Data Mining Approaches At ISPOR Europe 2019
Global Opioids Drugs Market is Projected to Grow At a CAGR of 2.52% by 2027 Reports Inkwood Research
Global Bio-Based Chemicals Market Projected to Grow At a CAGR of 16.67% by 2027 Finds Inkwood Research
The Global Animal Nutrition Market Projected to Grow At a CAGR of 5.94% by 2027 Finds Inkwood Research
FDA Approves Genentech’s Rozlytrek (entrectinib) for People With ROS1-Positive, Metastatic Non-small Cell Lung Cancer
BTG to Invest in Chinese Medical Isotope Diagnosis and Treatment Company Chengdu New Radiomedicine Technology

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business


Visit  La Bella Bakery Artisan Bakery Arizona


  ©2020 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (